Researchers make significant advance in treatment of bowel cancer
Can't see this email? View it online
   
  June 14, 2017  
  Bowel Cancer  
  The latest bowel cancer news from News Medical  
 Researchers make significant advance in treatment of bowel cancerResearchers make significant advance in treatment of bowel cancer
 
New research led by Queen's University Belfast has discovered how a genomic approach to understanding bowel (colorectal) cancer could improve the prognosis and quality of life for patients.
 
 
 Study shows effectiveness of 3 months of chemotherapy in colon cancer patients after surgeryStudy shows effectiveness of 3 months of chemotherapy in colon cancer patients after surgery
 
After surgery for lymph-node positive colon cancer (stage III), some patients may only need half of the long-standing standard course of chemotherapy.
 
   Novartis, Bristol-Myers Squibb collaborate to examine combination therapies for metastatic colorectal cancerNovartis, Bristol-Myers Squibb collaborate to examine combination therapies for metastatic colorectal cancer
 
Novartis today announced it has entered into a clinical research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist (trametinib) in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR).
 
   'Mismatch repair' genetic defects drive cancer patient's response to immunotherapy drugs'Mismatch repair' genetic defects drive cancer patient's response to immunotherapy drugs
 
In an expanded, three-year clinical trial of 86 patients with colorectal and 11 other kinds of cancer that have so-called 'mismatch repair' genetic defects, scientists at Johns Hopkins Medicine and its Bloomberg~Kimmel Institute for Cancer Immunotherapy have found that half of the patients respond to an immunotherapy drug called pembrolizumab.
 
   Scientists create 'immunoswitch' particles that slow cancer growth in test animalsScientists create 'immunoswitch' particles that slow cancer growth in test animals
 
Scientists at Johns Hopkins have created a nanoparticle that carries two different antibodies capable of simultaneously switching off cancer cells' defensive properties while switching on a robust anticancer immune response in mice.
 
 Study reveals cancer-fighting power of onions
 
Study reveals cancer-fighting power of onionsThe next time you walk down the produce aisle of your grocery store, you may want to reach for red onions if you are looking to fight off cancer.
 
 
 Berlin meeting of colorectal specialists to drive best practice and innovation
 
Berlin meeting of colorectal specialists to drive best practice and innovationIt is less than five months to go until the 2017 ESCP Meeting, which is taking place in Berlin between 20 and 21 September. The meeting, hosted by the European Society of Coloproctology, brings together global experts to drive innovation and best practice in the field and will feature the latest coloproctological research.
 
 
 New targeted oral therapy results in durable responses across many kinds of cancer
 
New targeted oral therapy results in durable responses across many kinds of cancerScientists may have developed the first targeted, oral, tumor-type agnostic therapy - a cancer medicine that works comparably well across many kinds of cancer, regardless of patient age. In clinical trials of adults and children with 17 different types of advanced cancer, larotrectinib treatment resulted in responses in 76% of patients.